Mesoporous Silica-Based Nanoplatforms Are Theranostic Agents for the Treatment of Inflammatory Disorders

Nanocarrier optimization: Encapsulating Hydrastis canadensis in chitosan nanoparticles for enhanced antibacterial and dye degradation performance

This study focuses on the optimization of Hydrastis canadensis-based nanocarriers in environmental and microbial applications like antibacterial and dye degradation. Hydrastis canadensis (H. canadensis) is loaded into the nanocarrier using a gelation method. Characterization involves pH analysis, UV-VIS spectrophotometry, scanning electron microscopy, Fourier-transform infrared spectroscopy, dynamic light scattering, high-performance liquid chromatography, encapsulation efficiency. Further antimicrobial activity against Staphylococcus aureus and Escherichia coli were tested. Dye degradation was evaluated at concentrations of 1 % of high molecular (HM) and 1.5 % of low molecular (LM) chitosan nanoparticles with both 3C and 1000C concentrations of the drug. The obtained results confirm the presence of chitosan nanocarrier alongside the pure drug in 1 % HM and 1.5 % LM chitosan particles with a notable encapsulation efficiency activity in both 3C and 1000C concentrations. Antimicrobial studies were carried out using the agar well diffusion method and revealed a significant zone of inhibition of 20 mm and 25 mm for E. coli and S. aureus, respectively in chitosan nanocarrier-loaded samples compared to pure drug and chitosan nanocarriers samples. The dye degradation studies of four dyes methylene blue, methylene orange, methylene red, and safranin using both pure drugs and chitosan nanocarrier-loaded drugs showed the highest percentage of degradation (76 %) against methylene blue in the chitosan nanocarrier-drug loaded formulation. These findings cumulatively underscore chitosan nanoparticles can be used as an effective carrier for Hydrastis Canadensis, with enhanced antimicrobial and dye degradation capabilities. Varied concentrations and molecular weights highlight the versatility of the ionotropic gelation method in optimizing drug delivery. Enhanced efficacy of the nanocarrier was evident in the observed zone of inhibition in antimicrobial testing. The substantial degradation percentage in methylene blue emphasizes the formulation's applicability in environmental dye removal processes, with potential avenues for improvement explored through interactions between the chitosan nanocarrier and H. canadensis characteristics. Future investigations may focus on scaling up the optimized formulation for large-scale applications and exploring release kinetics and comprehensive toxicity assessments for a holistic understanding of potential environmental and biomedical implications.

Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport

The nose-to-brain drug-delivery system has emerged as a promising strategy to overcome the challenges associated with conventional drug administration for central nervous system disorders. This emerging field is driven by the anatomical advantages of the nasal route, enabling the direct transport of drugs from the nasal cavity to the brain, thereby circumventing the blood-brain barrier. This review highlights the significance of the anatomical features of the nasal cavity, emphasizing its high permeability and rich blood supply that facilitate rapid drug absorption and onset of action, rendering it a promising domain for neurological therapeutics. Exploring recent developments and innovations in different nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, micelles, nanoemulsions, nanosuspensions, carbon nanotubes, mesoporous silica nanoparticles, and nanogels unveils their diverse functions in improving drug-delivery efficiency and targeting specificity within this system. To minimize the potential risk of nanoparticle-induced toxicity in the nasal mucosa, this article also delves into the latest advancements in the formulation strategies commonly involving surface modifications, incorporating cutting-edge materials, the adjustment of particle properties, and the development of novel formulations to improve drug stability, release kinetics, and targeting specificity. These approaches aim to enhance drug absorption while minimizing adverse effects. These strategies hold the potential to catalyze the advancement of safer and more efficient nose-to-brain drug-delivery systems, consequently revolutionizing treatments for neurological disorders. This review provides a valuable resource for researchers, clinicians, and pharmaceutical-industry professionals seeking to advance the development of effective and safe therapies for central nervous system disorders.

Triterpenes Drug Delivery Systems, a Modern Approach for Arthritis Targeted Therapy

Arthritis is a major cause of disability. Currently available anti-arthritic drugs, such as disease-modifying anti-rheumatic drugs (DMARDs), have serious side-effects associated with long-term use. Triterpenoids are natural products with known anti-inflammatory properties, and many have revealed efficiency against arthritis both in vitro and in vivo in several animal models, with negligible cytotoxicity. However, poor bioavailability due to low water solubility and extensive metabolism upon oral administration hinder the therapeutic use of anti-arthritic triterpenoids. Therefore, drug delivery systems (DDSs) able to improve the pharmacokinetic profile of triterpenoids and achieve sustained drug release are useful alternatives for targeted delivery in arthritis treatment. Several DDSs have been described in the literature for triterpenoid delivery, including microparticulate and nanoparticulate DDSs, such as polymeric micro and nanoparticles (NPs), polymeric micelles, liposomes, micro and nanoemulsions, and hydrogels. These systems have shown superior therapeutic effects in arthritis compared to the free drugs and are similar to currently available anti-arthritic drugs without significant side-effects. This review focuses on nanocarriers for triterpenoid delivery in arthritis therapy, including osteoarthritis (OA), rheumatoid arthritis (RA) and gout that appeared in the literature in the last ten years.

Nanotechnology development in surgical applications: recent trends and developments

This paper gives a detailed analysis of nanotechnology's rising involvement in numerous surgical fields. We investigate the use of nanotechnology in orthopedic surgery, neurosurgery, plastic surgery, surgical oncology, heart surgery, vascular surgery, ophthalmic surgery, thoracic surgery, and minimally invasive surgery. The paper details how nanotechnology helps with arthroplasty, chondrogenesis, tissue regeneration, wound healing, and more. It also discusses the employment of nanomaterials in implant surfaces, bone grafting, and breast implants, among other things. The article also explores various nanotechnology uses, including stem cell-incorporated nano scaffolds, nano-surgery, hemostasis, nerve healing, nanorobots, and diagnostic applications. The ethical and safety implications of using nanotechnology in surgery are also addressed. The future possibilities of nanotechnology are investigated, pointing to a possible route for improved patient outcomes. The essay finishes with a comment on nanotechnology's transformational influence in surgical applications and its promise for future breakthroughs.

Mesoporous Silica Nanoparticles as a Gene Delivery Platform for Cancer Therapy

Cancer remains a major global health challenge. Traditional chemotherapy often results in side effects and drug resistance, necessitating the development of alternative treatment strategies such as gene therapy. Mesoporous silica nanoparticles (MSNs) offer many advantages as a gene delivery carrier, including high loading capacity, controlled drug release, and easy surface functionalization. MSNs are biodegradable and biocompatible, making them promising candidates for drug delivery applications. Recent studies demonstrating the use of MSNs for the delivery of therapeutic nucleic acids to cancer cells have been reviewed, along with their potential as a tool for cancer therapy. The major challenges and future interventions of MSNs as gene delivery carriers for cancer therapy are discussed.